Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 23
Filter
1.
J Am Vet Med Assoc ; 243(9): 1291-7, 2013 Nov 01.
Article in English | MEDLINE | ID: mdl-24134578

ABSTRACT

OBJECTIVE: To determine efficacy of a single intra-articular injection of an autologous platelet concentrate for treatment of osteoarthritis in dogs. DESIGN: Randomized, controlled, 2-center clinical trial. ANIMALS: 20 client-owned dogs with osteoarthritis involving a single joint. PROCEDURES: Dogs were randomly assigned to a treatment or control group. In all dogs, severity of lameness and pain was scored by owners with the Hudson visual analog scale and the University of Pennsylvania Canine Brief Pain Inventory, respectively, and peak vertical force (PVF) was determined with a force platform. Dogs in the treatment group were then sedated, and a blood sample (55 mL) was obtained. Platelets were recovered by means of a point-of-use filter and injected intra-articularly within 30 minutes. Control dogs were sedated and given an intra-articular injection of saline (0.9% NaCl) solution. Assessments were repeated 12 weeks after injection of platelets or saline solution. RESULTS: Dogs weighed between 18.3 and 63.9 kg (40.3 and 140.6 lb) and ranged from 1.5 to 8 years old. For control dogs, lameness scores, pain scores, and PVF at week 12 were not significantly different from pretreatment values. In contrast, for dogs that received platelet injections, lameness scores (55% decrease in median score), pain scores (53% decrease in median score), and PVF (12% increase in mean PVF) were significantly improved after 12 weeks, compared with pretreatment values. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that a single intra-articular injection of autologous platelets resulted in significant improvements at 12 weeks in dogs with osteoarthritis involving a single joint.


Subject(s)
Dog Diseases/therapy , Osteoarthritis/veterinary , Platelet Transfusion/veterinary , Animals , Blood Platelets , Dogs , Female , Male , Osteoarthritis/therapy
2.
Tissue Eng Part C Methods ; 17(10): 993-8, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21609305

ABSTRACT

INTRODUCTION: We created the first tissue-engineered vascular graft (TEVG) to be successfully used in humans. The TEVG is made by seeding autologous bone marrow-derived mononuclear cells (BM-MNCs) onto a biodegradable tubular scaffold fabricated from polyglycolic-acid mesh coated with a 50:50 copolymer of poly-L-lactide and-ɛ-caprolactone. In the initial clinical study, the BM-MNCs were isolated using a Ficoll density centrifugation method. Use of this cell isolation technique is problematic in that it is performed using an open system and therefore is susceptible to contamination. As a first step toward creating a closed system for assembling a TEVG, we evaluated the use of a filter-based method for isolating BM-MNCs and compared it to density centrifugation in Ficoll. METHODS: BM-MNCs were isolated from human BM using density centrifugation in Ficoll or a filter-based method. BM-MNCs were seeded onto biodegradable tubular scaffold and incubated for 24 h before implantation. The TEVG were implanted as inferior vena cava interposition grafts in SCID/bg mice (n=24) using microsurgical technique. Grafts were followed with ultrasonography and computed tomography-angiography. Ten weeks after implantation the TEVG were explanted and examined using histology and immunohistochemistry. RESULTS: Both methods isolated similar number of cells (Ficoll: 8.5±6.6×10(6)/mL, Filter: 6.6±3.5×10(6)/mL; p=0.686) with similar viability as assayed using fluorescence-activated cell sorting (FACS) (Ficoll: 97.0%±1.5%, Filter: 95.9%±3.0%; p=0.339). FACS analysis demonstrated that the fraction of lymphocytes and monocytes to total cells was lower in the filter group (CD4 in Ficoll: 8.9%±1.1%, CD4 in Filter: 3.5%±0.8%; p=0.002, CD8 in Ficoll: 9.4%±2.1%, CD8 in Filter: 3.9%±1.4%; p=0.021, Monocyte in Ficoll: 6.9%±1.0%, Monocyte in Filter: 2.7%±1.0%; p=0.008), consistent with granulocyte contamination (Ficoll: 46.6±2.7×10(6)/mL, Filter: 58.1±5.2×10(6)/mL; p<0.001). The ratio of stem cells to BM-MNCs was comparable between groups. There were no statistically significant differences with regard to TEVG patency and morphology between groups. Both methods of cell isolation produced neovessels with similar histology. CONCLUSION: Filter-based BM-MNC isolation is comparable to BM-MNC isolation using density centrifugation in Ficoll for TEVG assembly. The filter-based cell isolation technique has the added advantage of the potential to create a closed disposable system.


Subject(s)
Blood Vessel Prosthesis , Bone Marrow Cells/cytology , Cell Separation/methods , Centrifugation, Density Gradient/methods , Filtration/instrumentation , Leukocytes, Mononuclear/cytology , Tissue Engineering/methods , Animals , Blood Vessels/diagnostic imaging , Blood Vessels/pathology , Flow Cytometry , Humans , Mice , Mice, SCID , Time Factors , Tomography, X-Ray Computed , Ultrasonography
3.
Am J Infect Control ; 38(1): 69-71, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19709779

ABSTRACT

Infections with Pseudomonas aeruginosa and other waterborne pathogens (WBPs) are major contributors to serious morbidity and mortality in hospitals. We sought to determine whether point-of-use (POU) water filtration might result in decreased risk of infection in the subacute care unit (SACU) of a 208-bed medical center. Our findings indicate that POU water filtration can significantly and cost-effectively reduce colonization of and infection with WBPs, including ventilator-associated pneumonia, in an SACU.


Subject(s)
Filtration/economics , Filtration/methods , Point-of-Care Systems/economics , Pseudomonas Infections/prevention & control , Subacute Care , Water Purification/economics , Water Purification/methods , Cost-Benefit Analysis , Humans , Prevalence
7.
Clin Infect Dis ; 45(8): 1008-13, 2007 Oct 15.
Article in English | MEDLINE | ID: mdl-17879916

ABSTRACT

Despite advances in the screening of donated blood for infectious agents, the risk of transmitting viral, bacterial, and protozoal infections, as well as newly emerging diseases, via transfusion persists. A complementary approach is leukocyte reduction (LR), the removal of leukocytes from donated blood by filtration. Published evidence, establishing the benefit of LR in reducing the risk of febrile nonhemolytic reactions, cytomegalovirus transmission, and human leukocyte antigen alloimmunization has led to its use for some time for the care of immunosuppressed and other individuals considered to be at high risk for such complications. Recent literature suggests that LR may be effective in reducing the risk of transmission of a number of additional transfusion-transmitted infectious agents, including herpesviruses, retroviruses, bacteria, protozoa, and prions. There is also evidence that LR may reduce the risk of transfusion-related immunomodulation, further contributing to protection against infections that would complicate treatment. With the mounting evidence of potential benefit, a number of countries, as well as many hospitals and blood centers in the United States, have adopted a policy of performing LR for all donated blood. Physicians who care for immunosuppressed patients and those who are responsible for institutional infection-control practices should remain informed of the growing body of literature on LR.


Subject(s)
Blood Transfusion , Communicable Disease Control/methods , Communicable Diseases/transmission , Leukocyte Reduction Procedures , Humans
8.
Neuroradiology ; 49(2): 93-102, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17177065

ABSTRACT

INTRODUCTION: Restoration of blood flow following ischemic stroke can be achieved by means of thrombolysis or mechanical recanalization. However, for some patients, reperfusion may exacerbate the injury initially caused by ischemia, producing a so-called "cerebral reperfusion injury". Multiple pathological processes are involved in this injury, including leukocyte infiltration, platelet and complement activation, postischemic hyperperfusion, and breakdown of the blood-brain barrier. METHODS/RESULTS AND CONCLUSIONS: Magnetic resonance imaging (MRI) can provide extensive information on this process of injury, and may have a role in the future in stratifying patients' risk for reperfusion injury following recanalization. Moreover, different MRI modalities can be used to investigate the various mechanisms of reperfusion injury. Antileukocyte antibodies, brain cooling and conditioned blood reperfusion are potential therapeutic strategies for lessening or eliminating reperfusion injury, and interventionalists may play a role in the future in using some of these therapies in combination with thrombolysis or embolectomy. The present review summarizes the mechanisms of reperfusion injury and focuses on the way each of those mechanisms can be evaluated by different MRI modalities. The potential therapeutic strategies are also discussed.


Subject(s)
Brain Ischemia/physiopathology , Reperfusion Injury/pathology , Reperfusion Injury/physiopathology , Brain Ischemia/pathology , Brain Ischemia/therapy , Cerebrovascular Circulation/physiology , Chemotaxis, Leukocyte/physiology , Humans , Magnetic Resonance Imaging , Platelet Activation/physiology , Reperfusion Injury/therapy
9.
J Clin Sleep Med ; 3(7): 700-5, 2007 Dec 15.
Article in English | MEDLINE | ID: mdl-18198803

ABSTRACT

RATIONALE: The treatment of choice for obstructive sleep apnea (OSA) is nasal continuous positive airway pressure (nCPAP) during sleep, but dryness of the upper airway compromises compliance. Heated humidifiers may mitigate such noncompliance; however, recent observations suggest that their use, particularly if not cleaned, increases the risk of respiratory infections. Humidifier water may be contaminated, but the long-held view that passive humidifiers cannot aerosolize water may obscure the perception of risk of infection. OBJECTIVES: This study challenges the long-held view that "passover" humidifiers do not aerosolize water. With such evidence, this study characterizes the performance of filters to reduce the potential risk of contamination. METHODS: Heated humidifier water contaminated with bacteria was studied under conditions simulating week-long use of nCPAP for OSA. RESULTS: Bacteria were recovered in 9 of 11 tests from the breathing tubes of CPAP devices fitted with heated humidifiers with water contaminated with Brevundimonas diminuta or Serratia marcescens. Recoverable bacteria ranged from tens to thousands of colony forming units when tested at air flow rates of 60 liters per minute for 90 minutes. Neither organism was recovered from the circuit tubing when a hydrophobic breathing-circuit filter was positioned between the humidifier and face-mask tubing with a commercially available nCPAP machine tested under simulated-use conditions. CONCLUSION: Data suggest that patients with OSA being treated with nCPAP fitted with humidifiers may be aerosolizing bacteria, putting them at risk for developing respiratory infections and that the use of a hydrophobic filter may attenuate the passage of microbes from contaminated humidifier water.


Subject(s)
Bacterial Infections/prevention & control , Continuous Positive Airway Pressure/instrumentation , Humidity , Micropore Filters , Respiratory Tract Infections/transmission , Water Microbiology , Aerosols , Bacterial Infections/microbiology , Bacteriological Techniques , Caulobacteraceae/growth & development , Colony Count, Microbial , Colony-Forming Units Assay , Equipment Design , Heating , Humans , Respiratory Tract Infections/microbiology , Respiratory Tract Infections/prevention & control , Serratia marcescens/growth & development
10.
Transfus Med Rev ; 20(3): 190-206, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16787827

ABSTRACT

Prions are infectious proteins believed to be responsible for a variety of progressive and fatal neurodegenerative diseases, collectively referred to as transmissible spongiform encephalopathies (TSE). By 1996, it was recognized that ingestion of beef from cattle afflicted with a TSE known as bovine spongiform encephalopathy, could result in a devastating human TSE known as variant Creutzfeldt-Jakob disease (vCJD). Two recent reports of probable transfusion-transmitted vCJD have raised concerns about the safety of the blood supply. The relatively long asymptomatic latency of vCJD, as well as the lack of sensitive and specific antemortem tests, increase the risk that asymptomatic, infected individuals may become blood donors. To this point, donor deferral has been a strategy used to reduce this risk. Nevertheless, this strategy may be unreliable and, furthermore, may threaten blood availability. Leukoreduction has also been helpful in reducing cell-associated infectious prion, which has been reported to reduce up to 42% of the infectivity in blood. Proprietary prion affinity surface modifications have been developed and applied to filters, which exploit an understanding of the unique chemical characteristics of prion surfaces. These have been successfully adapted to existing high-efficiency blood filter matrices for the reduction of prions present in blood components for transfusion.


Subject(s)
Creutzfeldt-Jakob Syndrome/prevention & control , Leukocyte Reduction Procedures/methods , Prions/isolation & purification , Transfusion Reaction , Chromatography, Affinity , Creutzfeldt-Jakob Syndrome/transmission , Filtration
11.
MLO Med Lab Obs ; 37(9): 10, 12, 14 passim; quiz 24-5, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16265819

ABSTRACT

Although eerily silent for many years after the recognition of scrapie in 1759, TSEs remained present within the genome of some mammals. Not since the mid-1950s when Dr. Carleton Gadjusek visited the Fore Indians of New Guinea to study kuru, however, has there been a more frenetic interest by governmental investigators. Certainly, the U.K. experience has heralded a renewed interest in TSEs due to the notoriety associated with younger subjects succumbing to a variant CJD traced to the ingestion of beef. Human TSEs and the potential for their transmission among and across species of mammals has also captured the attention of many. Yet, to date, there is no reliable antemortem test available to screen for infected animals or humans. Antibody-based assays are difficult to develop because most of them do not have specificity for the pathogenic form of prion protein. Whether or not prion testing efforts will change dramatically depends upon the incidence of disease. Some speculate a reduction in testing, because BSE incidence is waning since the adoption of remedial steps in the U.K. in 1989. Others remind us, however, of the long latency of prion diseases and of the recent observations of two patients who succumbed to vCJD after having received blood products from donors who subsequently died of vCJD. The growing incidence of CWD, combined with the emerging observation that as many as 26% of Alzheimer's patients may have been misdiagnosed--having died instead of prion disease--maintains pressure for legislators to adhere to the precautionary principle and support blood-donor exclusionary criteria, antemortem-test development, and pathogen removal from donated blood. The laboratorian can expect to see new tests for prion disease work their way into clinical-testing practice in the near future. In addition, the adoption of newer filtration technologies holds the promise of improved protection from transfusion-transmitted prion disease.


Subject(s)
Blood Transfusion , Prions/blood , Clinical Laboratory Techniques , Education, Continuing , Humans , Prions/pathogenicity , United States
12.
J Infus Nurs ; 28(4): 273-81, 2005.
Article in English | MEDLINE | ID: mdl-16106211

ABSTRACT

This article discusses the evidence for the generally accepted uses of leukocyte-reduced blood and the controversy over leukocyte reduction and transfusion-related immunomodulation. A perspective is provided on the continued need for leukocyte reduction on the part of all patients in the United States.


Subject(s)
Blood Transfusion , Evidence-Based Medicine , Leukapheresis , Patient Selection , Blood Transfusion/methods , Blood Transfusion/standards , Cytomegalovirus Infections/etiology , Cytomegalovirus Infections/prevention & control , Cytomegalovirus Infections/transmission , Fever/etiology , Fever/prevention & control , Humans , Infection Control/methods , Infection Control/standards , Isoantibodies/immunology , Leukapheresis/methods , Leukapheresis/standards , Leukocyte Count , Leukocytes/immunology , Leukocytes/virology , Mortality , Practice Guidelines as Topic , Transfusion Reaction
13.
Am J Infect Control ; 33(5 Suppl 1): S1-19, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15940112

ABSTRACT

Cholera, hepatitis and typhoid are well-recognized water-borne illnesses that take the lives of many every year in areas of uncontrollable flood, but far less attention is afforded to the allegedly safe potable water in affluent nations and the presumed healthful quality of water in communities and hospitals. Recent literature, however, points to increasing awareness of serious clinical sequelae particularly experienced by immunocompromised patients at high risk for disease and death from exposure to water-borne microbes in hospitals. This review reflects the literature indicting hospital water as an important source for nosocomial infections, examines patient populations at greatest risk, uncovers examples of failures in remedial water treatment methods and the reasons for them, and introduces point-of-use water filtration as a practical alternative or complementary component of an infection control strategy that may reduce the risk of nosocomial infections.


Subject(s)
Cross Infection/prevention & control , Filtration/instrumentation , Infection Control/instrumentation , Water Microbiology , Biofilms , Hospitals , Humans , Legionellosis/prevention & control , Risk Factors
14.
Transfusion ; 45(6): 984-93, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15934998

ABSTRACT

BACKGROUND: An enhanced bacterial detection system (Pall eBDS) was developed that distinguishes itself from its predecessor (Pall BDS) by removal of the platelet (PLT)-retaining filter allowing for optimal bacterial transfer, modification of the culture tablet to reduce the confounding effects of respiring PLTs while enhancing bacterial growth, and facilitation of nutrients and gas exchange by agitating the sample pouch during incubation at 35 degrees C. The objective was to evaluate the performance of the new eBDS. STUDY DESIGN AND METHODS: Leukoreduced whole blood-derived PLT concentrates (LR-PCs) and LR single-donor PLTs (LR-SDPs) were inoculated with 1 to 15 colony-forming units (CFUs) of bacteria per mL in studies of each of 10 bacterial species associated with fatal transfusion-transmitted bacterial infection. Immediately after inoculation and after 24 hours of storage at 22 degrees C, samples of inoculated LR-PCs were aseptically transferred into the eBDS pouches. Pouches were then incubated for 24 hours at 35 degrees C with agitation and oxygen concentration was then measured. RESULTS: Median inoculation levels ranged from 5 to 13 CFUs per mL for each species studied. No significant differences in oxygen concentration were found when comparing LR-PCs with LR-SDPs. When sampling occurred from the PLTs 24 hours after inoculation, all 280 cases (24-33 replicates of each species) were detected as contaminated by the device (100% sensitivity). No false-positives were obtained with 713 uninoculated PLT units. CONCLUSIONS: The eBDS demonstrated improved detection sensitivity in the range of 1 to 15 CFUs per mL with no observed false-positives compared to the original BDS (detection range 100 to 500 CFUs/mL) with no false-positives.


Subject(s)
Bacteria/isolation & purification , Bacterial Infections/prevention & control , Bacteriological Techniques/instrumentation , Bacteriological Techniques/methods , Oxygen Consumption , Bacterial Infections/transmission , Blood Platelets/microbiology , Evaluation Studies as Topic , Kinetics , Leukocytes/cytology , Platelet Count , Sensitivity and Specificity , Staphylococcus , Time Factors
15.
J Infus Nurs ; 27(3): 157-65, 2004.
Article in English | MEDLINE | ID: mdl-15118453

ABSTRACT

The first part of this 2-part series focused on the manufacture of filters and the application of filtration technology to intravenous fluids and point-of-care hospital water. This second part describes an apparent emerging potential for final filtration defined as bedside filtration of blood and component blood products leukocyte-reduced at the blood center prior to storage. Final filtration serves to further reduce the leukocyte burden in a previously leukocyte-reduced blood product. Another target for final filtration includes putative soluble mediators of morbidity.Selected patients may be at greater risk for alloimmunization and refractory to the benefits afforded by transfusion of blood leukocyte reduced to the current established standards. Multiparous patients who subsequently find themselves in need of a transplanted organ are alloimmunized by exposure to fetal proteins and may be further alloimmunized by transfusion. Such effects can put them at risk for increased latency for donor organ availability and organ rejection. Kidney transplant patients find themselves the recipients of transfused blood products particularly during end-stage renal disease and recent data suggest such patients are not benefited by the levels of leukoreduction prescribed by current standards and may need more dramatic leukocyte removal. The process of blood production is described and affords a greater appreciation for the levels of white cells found in component blood products. The development of alloimmunization is reviewed and fosters greater appreciation for a discussion of the potential for therapeutic value of more dramatic leukocyte reduction and blood conditioning accomplished through the removal of soluble mediators of morbidity.


Subject(s)
Blood Component Transfusion/instrumentation , Blood Component Transfusion/nursing , Filtration/methods , Leukocytes/immunology , Nursing Staff, Hospital , Blood Component Transfusion/adverse effects , Filtration/instrumentation , Humans , Point-of-Care Systems
16.
J Infus Nurs ; 27(2): 89-103, 2004.
Article in English | MEDLINE | ID: mdl-15085036

ABSTRACT

Filters often are viewed as screens with openings smaller than the particles intended to be removed by a process technically known as direct interception. However, filter manufacturing embraces far more advanced technological approaches, with an evolution toward selective removal of cells or soluble constituents from complex physiologic solutions. An appreciation of filtration development makes it easy to understand how differently manufactured filters with the same claims may not perform identically. This article focuses on the filtration of intravenous solutions and point-of-use hospital water.


Subject(s)
Drug Contamination/prevention & control , Equipment Contamination/prevention & control , Filtration/instrumentation , Infusions, Intravenous/instrumentation , Point-of-Care Systems , Water Purification/instrumentation , Biological Availability , Guidelines as Topic , Humans , Infection Control/methods , Infusions, Intravenous/adverse effects , Infusions, Intravenous/nursing , Particle Size , Phlebitis/etiology , Phlebitis/prevention & control , Sepsis/etiology , Sepsis/prevention & control , Solubility
17.
Transfusion ; 43(9): 1276-85, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12919431

ABSTRACT

BACKGROUND: The risk of receiving a PLT concentrate (PC) contaminated with bacteria may be 1000-fold greater than that of pathogenic viral transmission, yet surveillance for this risk is not generally practiced. A novel bacteria detection system (BDS) that overcomes the limitations of current systems is described. The BDS monitors percent oxygen (%O2) in air above aliquots of PCs that have been filtered to remove the confounding effect of respiring PLTs and residual WBCs. STUDY DESIGN AND METHODS: One-day-old WBC-reduced whole-blood-derived PCs (WBPCs) were inoculated with bacteria at 100 to 500 CFU per mL. After 30 minutes, 2- to 3-mL aliquots were processed through a PLT-reducing filter into a sample pouch containing sodium polyanethol sulfonate and entrained air. After incubation at 35 degrees C for at least 24 hours, the %O2 was measured within the pouch. Noninoculated WBC-reduced WBPCs (n = 155), confirmed free of bacteria by routine culture, were tested in a like manner. Results from the latter group of WBC-reduced WBPCs were used to distinguish contaminated from noncontaminated units. RESULTS: After a 24-hour incubation at 35 degrees C, 195 (96.5%) of the 202 sample pouches obtained from inoculated units were detected by the BDS. After an additional 6 hours at room temperature, those that remained and were tested were found positive. None of the noninoculated controls produced a positive reading. CONCLUSION: The BDS is easy to use and provides good levels of sensitivity and specificity.


Subject(s)
Bacteria/isolation & purification , Bacterial Infections/prevention & control , Bacteriological Techniques/methods , Blood Platelets/microbiology , Leukocytes/cytology , Oxygen/analysis , Bacteria/growth & development , Bacterial Infections/diagnosis , Bacterial Infections/transmission , Bacteriological Techniques/instrumentation , Biomarkers , Humans , Platelet Transfusion , Sensitivity and Specificity
18.
Transfus Med Rev ; 17(3): 216-22, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12881782

ABSTRACT

A historical perspective of the evolution of blood filtration is presented. Topics addressed include recognition of aggregates in blood as mediators of morbidity, targeted for removal with gross clot screens, and evolution through the implementation of universal leukocyte reduction. Future directions for the development of blood filters are also described.


Subject(s)
Blood Transfusion/history , Filtration/history , Leukocytes , Blood Component Removal/history , Blood Transfusion/instrumentation , Blood Transfusion/methods , Filtration/instrumentation , History, 17th Century , History, 18th Century , History, 20th Century , Humans
19.
Transfusion ; 43(6): 831-3; author reply 833-4, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12757541
SELECTION OF CITATIONS
SEARCH DETAIL
...